Dendritic Cell Therapy — Evidence and Availability in India

There is no reliable evidence that it does. Dendritic cell therapy has been studied for more than twenty-five years. Trials repeatedly show an immune response in the laboratory without a matching, dependable benefit for patients. No dendritic cell therapy is standard treatment for any cancer in India today.

That answer is blunt on purpose, because of who usually asks the question. It is normally a son, a daughter or a spouse, holding a quotation from a private centre, a few days after a diagnosis. The offer arrives with a scientific-sounding explanation, a laboratory photograph, and a price. It is being sold commercially, at high cost, by centres operating outside the approval system — and the single most useful thing this page can do is give you the questions that expose that in ten minutes.

It also helps to know where the confusion starts. The immunotherapy that hospitals actually give works by releasing a brake on immune cells that are already present, and is prescribed only when biomarker testing and the stage of disease support it. Dendritic cell therapy is a different idea altogether: the patient’s own cells are collected, handled in a laboratory and given back. Both get called “immunotherapy”, which is exactly why a family can be told they are being offered the same class of treatment when they are not. CION does not provide, administer or stock dendritic cell therapy or any other cell therapy product.

Regulatory and cost position is indicative, as of August 2026, and follows the CDSCO framework together with NCCN and ESMO patient-education material. Approval status can change — ask to see the written approval for the exact product, and check its date.

This page discusses practices, not businesses. No product name appears here, and nothing on this page compares one commercial offering with another.

1. 1

   Cells are collected

   White cells are taken from the blood, usually through an apheresis machine over a few hours. This step alone has its own risks and needs proper monitoring.

2. 2

   They are matured in a laboratory

   Over about a week, growth factors turn precursor cells into dendritic cells. The quality of that facility matters enormously, and is the part a patient can never see.

3. 3

   They are loaded with a target

   The cells are exposed to tumour proteins, to material from the patient’s own tumour, or to genetic instructions for a target, so they carry something recognisable.

4. 4

   They are given back

   Usually as a series of injections or infusions over weeks. Fever, flu-like symptoms and injection-site reactions are the commonly described effects.

5. 5

   This is the step that fails

   T cells must then multiply and reach the tumour. Tumours actively suppress immune activity around themselves, and this is where decades of trials have come apart — a laboratory response without a clinical one.

Understanding this sequence is the point: the mechanism being plausible is precisely why the therapy keeps being sold, and plausibility is not the same as evidence.

Positions are indicative, as of August 2026. CION does not provide CAR-T or any cell therapy; where such treatment is genuinely relevant, patients are referred to a licensed centre. Response-assessment PET-CT is coordinated at partner imaging centres.

• “Show me the CDSCO approval for this exact product.” A laboratory licence, an accreditation certificate or a company brochure is not a drug approval. Ask which document it is, and read the date on it.
• “Is this a registered clinical trial? What is the CTRI number?” Ask which ethics committee approved the protocol, and ask why the patient is being charged for an investigational product, if you are.
• “Which guideline recommends this for my cancer, at my stage?” NCCN and ESMO pathways are public documents. Ask for the page reference, not a summary of it.
• “What happens to my standard treatment while I do this?” This is the question that matters most. Delaying or pausing evidence-based treatment is the commonest way an unproven therapy causes real harm.
• “What is the total cost, and what if I stop after one cycle?” Get the full course price and the refund position in writing before any money moves.
• “Will you write to my treating oncologist?” A refusal, or a suggestion that your oncologist need not know, tells you everything you need.

None of this is about ridiculing anyone’s hope, or anyone’s faith in a system of medicine they trust. Families explore Ayurveda, homeopathy and religious practice alongside cancer treatment, and that is their own business. The one thing we ask is disclosure: tell the treating team what has been taken or given, so that a fever, a blood count or a scan can be read correctly.

• NK Cell Therapy and Other Cell Treatments Offered Privately — the closest neighbour to this page: the same commercial pattern, a different cell type, and the same evidence problem.
• Ozone, Hyperthermia and ‘Immune’ Therapies Sold to Cancer Patients — if the same centre has also offered ozone, hyperthermia or an immunity drip, this covers what those are.
• Bispecific Antibodies for Blood Cancers — what an approved, evidence-backed way of directing T cells at a tumour actually looks like, for comparison.
• Immunotherapy at CION Cancer Clinics — the hub page: which immunotherapy CION does give, how eligibility is decided, and how it is administered as day care.

This page is general information and does not replace a consultation. It describes classes of treatment and regulatory position only, names no product and no centre, and makes no claim of benefit for any therapy discussed. Regulatory and cost details are indicative, as of August 2026. Decisions about your own treatment must be made with your treating oncologist.

Families bring us this offer almost every week

Asking is sensible, not naive. Our team will take the time to explain what is approved, what is still being studied, and what is simply being sold.